NRX Pharmaceuticals annual free cash flow
2020
2021
2022
2023
2024
NRX Pharmaceuticals reported −$10.6M in free cash flow for fiscal 2024, an increase of $11.0M from the previous fiscal year.
View full NRX Pharmaceuticals company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$10.6M | $11.0M | — | — |
| 2023 | 2023-12-31 | −$21.7M | $18.1M | — | — |
| 2022 | 2022-12-31 | −$39.8M | −$2.1M | — | — |
| 2021 | 2021-12-31 | −$37.7M | −$35.4M | — | — |
| 2020 | 2020-12-31 | −$2.3M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | −$3.5M | $191,000 | — | — |
| Q4 2024 | 2024-12-31 | −$2.1M | $1.1M | — | — |
| Q3 2024 | 2024-09-30 | −$2.3M | $2.3M | — | — |
| Q2 2024 | 2024-06-30 | −$2.6M | $5.3M | — | — |
| Q1 2024 | 2024-03-31 | −$3.7M | $2.4M | — | — |
| Q4 2023 | 2023-12-31 | −$3.2M | $5.1M | — | — |
| Q3 2023 | 2023-09-30 | −$4.6M | $1.7M | — | — |
| Q2 2023 | 2023-06-30 | −$7.8M | $7.0M | — | — |
| Q1 2023 | 2023-03-31 | −$6.1M | $4.3M | — | — |
| Q4 2022 | 2022-12-31 | −$8.3M | $3.7M | — | — |
| Q3 2022 | 2022-09-30 | −$6.3M | — | — | — |
| Q2 2022 | 2022-06-30 | −$14.8M | — | — | — |
| Q1 2022 | 2022-03-31 | −$10.4M | — | — | — |
| Q3 2021 | 2021-09-30 | −$12.0M | — | — | — |
NRX Pharmaceuticals's latest reported quarter, Q1 2025, generated −$3.5M in free cash flow, an increase of $191,000 year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review NRX Pharmaceuticals filings at SEC.gov ↗